{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,8,18]],"date-time":"2023-08-18T04:23:28Z","timestamp":1692332608051},"reference-count":13,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,2]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n          <jats:p>Ibrutinib is a new first-line drug for treating chronic lymphocytic leukemia (CLL), and could change frontline treatment of CLL from traditional IV chemotherapy to oral targeted therapy. Lymphocytosis often worsens with initiation of ibrutinib, but typically resolves over 6 to 18 months. Though patients generally tolerate ibrutinib well, the drug can cause adverse reactions including hypertension, atrial fibrillation, bleeding, and infections such as fungal pneumonia.<\/jats:p>","DOI":"10.1097\/01.jaa.0000651764.99857.a5","type":"journal-article","created":{"date-parts":[[2020,1,28]],"date-time":"2020-01-28T21:59:34Z","timestamp":1580248774000},"page":"51-53","source":"Crossref","is-referenced-by-count":0,"title":["An oral drug for chronic lymphocytic leukemia"],"prefix":"10.1097","volume":"33","author":[{"given":"Amber","family":"Koehler","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"issue":"5","key":"R1-20230817","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1056\/NEJMoa1817073","article-title":"Ibrutinib-rituximab or chemoimmunotherapy for chronic lymphocytic leukemia","volume":"381","author":"Shanafelt","year":"2019","journal-title":"N Engl J Med"},{"issue":"26","key":"R2-20230817","doi-asserted-by":"crossref","first-page":"2517","DOI":"10.1056\/NEJMoa1812836","article-title":"Ibrutinib regimens versus chemoimmunotherapy in older patients with untreated CLL","volume":"379","author":"Woyach","year":"2018","journal-title":"N Engl J Med"},{"issue":"12","key":"R3-20230817","doi-asserted-by":"crossref","first-page":"1799","DOI":"10.1182\/bloodadvances.2018028761","article-title":"Long-term safety of single-agent ibrutinib in patients with chronic lymphocytic leukemia in 3 pivotal studies","volume":"3","author":"Coutre","year":"2019","journal-title":"Blood Adv"},{"issue":"12","key":"R4-20230817","doi-asserted-by":"crossref","first-page":"1571","DOI":"10.3324\/haematol.2015.126672","article-title":"Incidence and risk factors of bleeding-related adverse events in patients with chronic lymphocytic leukemia treated with ibrutinib","volume":"100","author":"Lipsky","year":"2015","journal-title":"Haematologica"},{"issue":"17","key":"R5-20230817","doi-asserted-by":"crossref","first-page":"1910","DOI":"10.1182\/blood-2017-10-810044","article-title":"Single-agent ibrutinib in treatment-na\u00efve and relapsed\/refractory chronic lymphocytic leukemia: a 5-year experience","volume":"131","author":"O'Brien","year":"2018","journal-title":"Blood"},{"issue":"5","key":"R7-20230817","doi-asserted-by":"crossref","first-page":"365","DOI":"10.3816\/CLM.2009.n.071","article-title":"Infectious complications in patients with chronic lymphocytic leukemia: pathogenesis, spectrum of infection, and approaches to prophylaxis","volume":"9","author":"Morrison","year":"2009","journal-title":"Clin Lymphoma Myeloma"},{"issue":"17","key":"R8-20230817","doi-asserted-by":"crossref","first-page":"1955","DOI":"10.1182\/blood-2017-11-818286","article-title":"Early-onset invasive aspergillosis and other fungal infections in patients treated with ibrutinib","volume":"131","author":"Ghez","year":"2018","journal-title":"Blood"},{"issue":"1","key":"R9-20230817","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1093\/cid\/cix687","article-title":"Call for action: invasive fungal infections associated with ibrutinib and other small molecule kinase inhibitors targeting immune signaling pathways","volume":"66","author":"Chamilos","year":"2018","journal-title":"Clin Infect Dis"},{"issue":"6","key":"R10-20230817","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1056\/NEJMoa1306220","article-title":"Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma","volume":"369","author":"Wang","year":"2013","journal-title":"N Engl J Med"},{"issue":"4","key":"R11-20230817","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1111\/bjh.15690","article-title":"Incidence of and risk factors for major haemorrhage in patients treated with ibrutinib: an integrated analysis","volume":"184","author":"Brown","year":"2019","journal-title":"Br J Haematol"},{"issue":"1","key":"R12-20230817","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1056\/NEJMoa1215637","article-title":"Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia","volume":"369","author":"Byrd","year":"2013","journal-title":"N Engl J Med"},{"issue":"15 suppl","key":"R13-20230817","doi-asserted-by":"crossref","first-page":"7525","DOI":"10.1200\/JCO.2018.36.15_suppl.7525","article-title":"Rapid progression of disease following ibrutinib discontinuation in patients with chronic lymphocytic leukemia","volume":"36","author":"Hampel","year":"2018","journal-title":"J Clin Oncol"},{"issue":"21","key":"R14-20230817","doi-asserted-by":"crossref","first-page":"2249","DOI":"10.1182\/blood-2018-06-860593","article-title":"A pilot study of lower doses of ibrutinib in patients with chronic lymphocytic leukemia","volume":"132","author":"Chen","year":"2018","journal-title":"Blood"}],"container-title":["JAAPA"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/01.JAA.0000651764.99857.a5","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,17]],"date-time":"2023-08-17T23:30:14Z","timestamp":1692315014000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/01.JAA.0000651764.99857.a5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2]]},"references-count":13,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2020]]}},"URL":"https:\/\/doi.org\/10.1097\/01.jaa.0000651764.99857.a5","relation":{},"ISSN":["1547-1896"],"issn-type":[{"value":"1547-1896","type":"print"}],"subject":[],"published":{"date-parts":[[2020,2]]}}}